Jianda Yuan Selected Research

CTLA-4 Antigen

1/2020	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
1/2016	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
1/2014	Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.
10/2011	Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
5/2010	Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
12/2008	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jianda Yuan Research Topics

Disease

36	Neoplasms (Cancer) 01/2022 - 08/2004
28	Melanoma (Melanoma, Malignant) 01/2020 - 11/2007
4	Human Influenza (Influenza) 03/2016 - 01/2005
3	Infections 12/2012 - 05/2010
2	Breast Neoplasms (Breast Cancer) 12/2016 - 10/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2016 - 03/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 10/2010
2	Hypersensitivity (Allergy) 08/2013 - 07/2010
2	Testicular Neoplasms (Testicular Cancer) 03/2012 - 10/2011
1	Microsatellite Instability 01/2020
1	Inflammation (Inflammations) 01/2018
1	Prostatic Neoplasms (Prostate Cancer) 01/2018
1	Exanthema (Rash) 12/2016
1	Neoplasm Metastasis (Metastasis) 03/2016
1	Lymphatic Metastasis 03/2016
1	Lung Neoplasms (Lung Cancer) 04/2015
1	Adenocarcinoma 03/2014
1	Fatigue 03/2014
1	Pain (Aches) 03/2014
1	Communicable Diseases (Infectious Diseases) 08/2013
1	Vitiligo 01/2013
1	Lymphopenia (Lymphocytopenia) 10/2012
1	Poxviridae Infections 01/2012
1	Vaccinia 01/2012
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 08/2011
1	Mesothelioma 10/2010
1	Thoracic Neoplasms 10/2010
1	Malignant Mesothelioma 10/2010
1	Pathologic Complete Response 07/2010

Drug/Important Bio-Agent (IBA)

20	IpilimumabIBA 01/2020 - 12/2008
13	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2011
10	AntigensIBA 01/2016 - 07/2009
8	VaccinesIBA 01/2016 - 09/2007
7	CytokinesIBA 12/2016 - 05/2010
7	Peptides (Polypeptides)IBA 04/2011 - 08/2004
6	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2014
6	CTLA-4 AntigenIBA 01/2020 - 12/2008
5	DNA (Deoxyribonucleic Acid)IBA 10/2016 - 11/2007
5	AntibodiesIBA 01/2016 - 01/2011
5	Monophenol Monooxygenase (Tyrosinase)IBA 01/2013 - 09/2007
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2012
3	Neoplasm Antigens (Tumor Antigens)IBA 12/2016 - 10/2011
3	Interleukin-10 (Interleukin 10)IBA 02/2015 - 05/2010
3	DNA VaccinesIBA 01/2013 - 11/2007
3	Oncogene Proteins (Oncogene Protein)IBA 06/2012 - 07/2010
3	Interferon-gamma (Interferon, gamma)IBA 10/2010 - 09/2007
3	HLA-A*02:01 antigenIBA 11/2007 - 01/2005
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2016 - 01/2015
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2016 - 12/2008
2	EpitopesIBA 01/2013 - 01/2005
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2013 - 11/2007
2	Monoclonal AntibodiesIBA 10/2011 - 12/2008
2	Differentiation AntigensIBA 06/2009 - 11/2007
1	LigandsIBA 01/2020
1	Alkylating AgentsIBA 01/2018
1	Melphalan (Alkeran)FDA LinkGeneric 01/2018
1	Mechlorethamine (Nitrogen Mustard)FDA Link 01/2018
1	Dihydrotachysterol (AT 10)IBA 12/2016
1	Hematoxylin (Haematoxylon)IBA 10/2016
1	Eosine Yellowish-(YS) (Eosin)IBA 10/2016
1	Methadone (Dolophine)FDA LinkGeneric 03/2016
1	Heroin (Diamorphine)IBA 03/2016
1	6-sulfo sialyl Lewis XIBA 03/2016
1	ChemokinesIBA 03/2016
1	Chemokine ReceptorsIBA 03/2016
1	CCR ReceptorsIBA 03/2016
1	RNA (Ribonucleic Acid)IBA 01/2016
1	pembrolizumabIBA 04/2015
1	Indicators and Reagents (Reagents)IBA 02/2015
1	tremelimumabIBA 12/2014
1	3,4-methylenedioxyethamphetamine (MDEA)IBA 03/2014
1	Interleukin-4 (Interleukin 4)IBA 03/2014
1	Interleukin-6 (Interleukin 6)IBA 03/2014
1	Transforming Growth Factor beta (TGF-beta)IBA 03/2014
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014
1	Protein Isoforms (Isoforms)IBA 06/2012
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 06/2012
1	Integrin alpha4beta1 (VLA-4)IBA 06/2012
1	Viral RNAIBA 01/2012
1	Z-Form DNA (Z-DNA)IBA 01/2012
1	Toll-Like Receptor AgonistsIBA 01/2012
1	EnzymesIBA 08/2011
1	Imatinib Mesylate (Gleevec)FDA Link 08/2011
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 08/2011
1	MART-1 AntigenIBA 08/2011
1	Interleukin-2 (IL2)IBA 04/2011
1	Interleukin-15 (Interleukin 15)IBA 04/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2011
1	Blocking AntibodiesIBA 01/2011
1	Costimulatory and Inhibitory T-Cell ReceptorsIBA 01/2011
1	GlucocorticoidsIBA 01/2011
1	Transcription Factors (Transcription Factor)IBA 10/2010
1	Protein Subunit VaccinesIBA 07/2010

Therapy/Procedure

16	Immunotherapy 11/2021 - 09/2007
15	Therapeutics 01/2018 - 01/2010
3	Drug Therapy (Chemotherapy) 01/2018 - 10/2012
2	Cryosurgery 12/2016 - 10/2016
1	Mastectomy (Mammectomy) 12/2016
1	Hematopoietic Stem Cell Transplantation 12/2012
1	Radiotherapy 03/2012